Expanding Opportunities for Specialty Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Expanding Opportunities for Specialty Excipients
China creates a potential outlet for specialty excipients as its pharmaceutical market grows.


Pharmaceutical Technology


The study describes the dissolution testing of several disintegrants and eight cationic drug actives formulated in direct-compression tablets, all prepared using a model formulation. The test disintegrants included Polyplasdone XL Crospovidone, Polyplasone XL-10 Crospovidone superdisintegrants, and the anionic disintegrants sodium starch glycolate and croscarmellose sodium. Polyplasdone XL Crospovidone and Polyplasone XL-10 Crospovidone are synthetic, insoluble, but swellable, cross-linked homopolymers of N-vinyl-2-pyrrolidone that differ only in particle size.

ISP reported that the two disintegrants (Polyplasdone XL Crospovidone, Polyplasone XL-10 Crospovidone) provide fast dissolution not only for freely soluble, cationic drug actives such as chlorpromazine hydrochloride, ranitidine hydrochloride, cetirizine hydrochloride, and venlafaxine hydrochloride, but also for cationic actives with low water solubility such as ciprofloxacin hydrochloride, fexofenadine hydrochloride, terbi-nafine hydrochloride, and clopidogrel bisulfate.

References

1. G. S. Morris and J.Huang, "China Emerges as the Next Frontier for Specialty Excipients," Pharm. Technol. 30 Technology Outlook; APIs, Intermediates, and Formulation supplement, s26–s30 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here